Backed by NEA and Norwest.
About the role
If you’re passionate about advancing innovative treatments for patients and shaping the future of precision peptide therapeutics, this is your chance to make a real impact alongside a fast-paced, growing, mission-driven team. To learn more, visit our website mbxbio.com and follow us on LinkedIn .
What they're looking for
- Lead day‑to‑day clinical data management operations across MBX programs
- Provide oversight of EDC and eDiary/eCOA design, development, and ongoing database modifications, including review and approval of specifications. Ensure core team’s input is incorporated for robust design
- Oversee and perform User Acceptance Testing (UAT), validation activities, and documentation to ensure compliant, high‑quality databases
- Develop, maintain, and update Data Management Plans (DMPs), CRF Completion Guidelines (CCGs), and related DM documentation
- Lead data review meetings, including delivery of data listings to clinical and medical teams
- Lead proactive data surveillance and critical data reviews/reconciliations to ensure data completeness, quality, and timely availability of primary and key secondary endpoint data
More about this role
Working with Us
MBX Biosciences is a clinical-stage biopharmaceutical company headquartered in Carmel, Indiana, with a secondary office in Burlington, MA. Our mission is to transform the lives of people impacted by endocrine and metabolic disorders through our novel precision peptides.
Leveraging our proprietary Precision Endocrine Peptides (PEPs)™ platform, we are pioneering technology designed to overcome key limitations of existing therapies and enhance efficacy, tolerability, safety and convenience. Our team is advancing a pipeline of novel candidates with clinically validated targets, established endpoints for regulatory approval, and strong market potential.
Our pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism, currently preparing for Phase 3 development, and a growing obesity portfolio that includes MBX 4291 in Phase 1 development, MBX 5765, a next-generation amycretin prodrug designed for once-monthly-dosing, as well as MBX 6180, a GLP/GIP/GCGR triple agonist prodrug for once monthly dosing; all of which optimize our PEP platform.
If you’re passionate about advancing innovative treatments for patients and shaping the future of...
Browse similar: Startup jobs